Top Abstract Purchase Related
Home
>
Node
>
Subnode

Double hemibody irradiation in chemotherapy-resistant multiple myeloma

Thomas, P.J.; Daban, A.; Bontoux, D.

Cancer Treatment Reports 68(9): 1173-1175

1984

ISSN/ISBN: 0361-5960
PMID: 6383606
Document Number: 223958
Seven patients with high-mass multiple myeloma resistant to chemotherapy were treated by double hemibody irradiation (DHI). The total-body myeloma cell mass decreased from 38% to 80% for the five patients who received a complete treatment. Pain and performance status were improved. Hematological toxicity was severe, and one patient died after 3 months from marrow aplasia. Survival from 3 to greater than 19 months was obtained after the completion of DHI. According to our experiment, DHI can be considered as a treatment of last resort for resistant multiple myeloma.

Document emailed within 1 workday
Secure & encrypted payments

Morstyn, G.; Schechter, G.P.; Ihde, D.C.; Carney, D.N.; Eddy, J.L.; Cohen, M.H.; Minna, J.D.; Bunn, P.A. 1984: Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness Cancer Treatment Reports 68(12): 1439-1446
Kuban, D.A.; Schellhammer, P.F.; el-Mahdi, A.M. 1991: Hemibody irradiation in advanced prostatic carcinoma Urologic Clinics of North America 18(1): 131-137
Vinciguerra, V.; Anderson, K.; McIntyre, O.R. 1985: Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B Cancer Treatment Reports 69(3): 331-332
Sezaki, T. 1989: Current results of chemotherapy in multiple myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(5): 1997-2003
Tribalto, M.; Arcese, W.; Colombo, R.; Pastore, S.; Franchii, A. 1981: Chemotherapy of multiple myeloma. Review of the recent trials Recenti Progressi in Medicina 71(2): 141-147
Alexanian, R.; Migliore, P.J. 1970: Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy Journal of Laboratory and Clinical Medicine 75(2): 225-233
Kasili, E.G. 1976: Current trends in chemotherapy of leukaemias lymphomas and multiple myeloma East African Medical Journal 53(9): 554-559
Weber, D.M. 2003: Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation Oncology 17(6): 765-767
Bataille, R.; Morlock, G.; Rosenberg, F.; Sany, J.; Serre, H. 1979: Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 55(31-32): 1377-1382
Alberts, D.S.; Golde, D.W. 1974: DNA synthesis in multiple myeloma cells following cell cycle-nonspecific chemotherapy Cancer Research 34(11): 2911-2914
Kurihara, K.; Hill, W.; Burkhardt, R.; Kettner, G.; Hashimoto, N. 1987: Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 50(4): 876-889
Li, J.; Zhao, Y.; Luo, S.-K.; Huang, B.-H.; Zhang, G.-C.; Peng, A.-H.; Zheng, D.; Su, C.; Xu, D.-R.; Tong, X.-Z.; Gu, J.-L.; Ding, Y. 2008: The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma Zhonghua Yi Xue Za Zhi 88(30): 2140-2143
Golenkov, A.K.; Mitina, T.A.; Kogarko, I.N.; Liubimova, N.V.; Klinushkina, E.F.; Baryshnikov, A.I. 2009: Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins Terapevticheskii Arkhiv 81(7): 37-41
Golenkov, A.K.; Trifonova, E.V.; Kataeva, E.V.; Kil'diushevskiĭ, A.V.; Lutskaia, T.D.; Zariad'eva, E.A.; Nazarova, I.N.; Lukashina, M.N.; Zabotina, T.N.; Mikhaĭlova, I.N.; Inshakov, A.N.; Logacheva, N.P.; Baryshnikov, A.Iu. 2000: Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy Terapevticheskii Arkhiv 72(8): 38-41
Ludwig, H.; Fritz, E. 1981: Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells Anticancer Research 1(6): 329-334
Li, X.; Sun, W.; Jin, F.; Chen, S.; Zhong, Y.; Hu, Y.; Zhang, J.; An, N.; Shen, M.; Huang, Z. 2014: Clinical observation of DECP combination chemotherapy for relapsing and refractory multiple myeloma patients with extramedullary plasmacytomas Zhonghua Yi Xue Za Zhi 94(16): 1258-1260
Dreyfus, F.; Ribrag, V.; Leblond, V.; Ravaud, P.; Melle, J.; Quarre, M.C.; Pillier, C.; Boccaccio, C.; Varet, B. 1995: Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma Bone Marrow Transplantation 15(5): 707-711
Palumbo, A.P.; Garino, A.L.; Frieri, R.; Gallone, G.; Boccadoro, M.; Pileri, A. 1990: Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy Haematologica 75(6): 576-578
Kuwakado, S.; Takiuchi, H.; Goto, M.; Kawabe, S.; Ohta, S.; Kii, T.; Tanaka, T.; Nishitani, H.; Katsu, K.-i. 2006: A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(4): 513-515
Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.; Coleman, R.E.; Reitsma, D.J.; Seaman, J.J.; Chen, B.L.; Ambros, Y. 2001: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer Journal 7(5): 377-387